Bradycardia
Clinical Snapshot
"Bradycardia" literally means a heart rate slower than normal — clinically, a resting heart rate under 60 beats per minute. That single threshold alone does not distinguish a normal, healthy finding (a fit 25-year-old with a resting rate of 48 bpm) from a dangerous one (an 80-year-old with syncope and a resting rate of 45 bpm), which is why this chapter organizes bradycardia around three overlapping categories that actually dictate management: sinus node dysfunction (SND — the modern term for what is still often called "sick sinus syndrome"), atrioventricular (AV) block, and — the angle pharmacists are most often first to recognize — drug-induced or drug-exacerbated bradycardia, which can affect either mechanism, or both at once, most often when interacting drugs are layered together.
Two questions dominate every bradycardia work-up, whether it starts at the bedside or at the pharmacy counter: is the bradycardia genuinely producing symptoms, and is there a reversible or physiologic cause? Neither the CCS/CHRS nor the ACC/AHA/HRS approach uses a minimum heart rate or pause duration to trigger permanent pacing in an asymptomatic patient — establishing a real temporal correlation between symptoms and the bradycardia is what matters.[1][2] The major exception is Mobitz type II second-degree AV block, advanced/high-grade AV block, and third-degree (complete) AV block: once a reversible or physiologic cause has genuinely been excluded, permanent pacing is recommended for these specifically regardless of symptoms.[2][1]
For a community or hospital pharmacist, the practical stakes run in both directions. Missing that a new drug or dose increase — a non-dihydropyridine calcium channel blocker added to an existing beta-blocker, a cholinesterase inhibitor started in a frail older adult, a digoxin level drifting up as renal function declines — is driving a patient's fatigue or falls is a real, correctable harm. But the opposite error is just as real: assuming that any bradycardia in a patient taking one of these drugs is simply "the drug" and can be managed by stopping it alone. Genuine drug-induced advanced AV block is uncommon, and recurrence after stopping the presumed culprit is common — particularly in older, frailer patients whose conduction disease was most likely present, if quiet, before the drug was ever started.[3]
Recognize the Condition
Typical presentation
Symptoms range from none at all to a genuine cardiac emergency, which is exactly why establishing a real correlation between symptoms and the bradycardia — not the heart rate number alone — is the central diagnostic task.
- Entirely asymptomatic, found incidentally on a routine ECG, a pharmacy blood-pressure-machine pulse reading, or a wearable device.
- Fatigue, reduced exercise tolerance, and dyspnea on exertion — often attributed to "getting older" or deconditioning before bradycardia is recognized as the actual cause.
- Chronotropic incompetence: an inability to raise the heart rate appropriately with exertion, described by patients as exercise intolerance rather than a "slow pulse."
- Lightheadedness, presyncope, or frank syncope — syncope from bradycardia is a red flag (see Red Flags/Refer).
- Confusion or a subtle cognitive decline in an older adult, sometimes the only presenting feature.
- Symptoms of worsening heart failure, when a slow rate can no longer maintain adequate cardiac output in a patient with reduced ventricular function.
Physiologic vs. pathologic bradycardia — the first branch point
Two very different pictures with the same heart rate
Physiologic (do not treat)
High-level athletic conditioning is the classic cause — resting rates in the 40s, occasionally the 30s, are a normal training adaptation.[2] The rate is asymptomatic, rises appropriately with exertion, and there is no history of syncope or presyncope. Sleep-related sinus bradycardia and brief nocturnal pauses are also usually physiologic and are not, by themselves, an indication for pacing.[2]
Pathologic (investigate)
Bradycardia in an older adult, especially with symptoms, a blunted or absent heart-rate response to exertion, or a new pattern with no physiologic explanation, warrants a genuine work-up rather than reassurance. Age-dependent progressive fibrosis of the sinus node and surrounding atrial tissue is the single most common underlying cause of sinus node dysfunction overall.[2]
Classification — three overlapping categories
What kind of bradycardia is this?
Sinus node dysfunction (SND)
Encompasses sinus bradycardia (a sinus rate under 50 bpm on the technical, pathology-oriented definition — distinct from the general <60 bpm clinical bradycardia threshold), ectopic atrial bradycardia, sinoatrial exit block, sinus pauses (>3 seconds) and sinus arrest, tachycardia-bradycardia ("tachy-brady") syndrome — sinus bradycardia or pause alternating with an atrial tachyarrhythmia such as atrial fibrillation — and chronotropic incompetence. "Sick sinus syndrome" is an older umbrella term for symptomatic SND still in common clinical use.[2]
Atrioventricular (AV) block
Classified by degree: first-degree (PR interval >200 ms, every beat still conducted — technically an AV delay rather than a true block); second-degree Mobitz type I/Wenckebach (progressively lengthening PR interval before a dropped beat — usually AV-nodal and comparatively benign); second-degree Mobitz type II (a sudden dropped beat with constant PR intervals before and after — more often infranodal, and can progress abruptly to complete block); 2:1 AV block (every other P wave conducts — cannot be classified as Mobitz I or II without more information); advanced/high-grade AV block (2 or more consecutive P waves fail to conduct despite evidence of some remaining AV conduction); and third-degree (complete) AV block (no P wave conducts to the ventricles at all — see the ECG above).[2]
Conduction tissue disease
Bundle branch and fascicular block are conduction disorders rather than bradycardia in themselves, but a newly identified left bundle branch block substantially raises the likelihood of underlying structural heart disease and warrants an echocardiogram.[2]
Risk Factors
Non-drug causes
- Age-related degenerative fibrosis of the sinus node and conduction system — the single most common cause of sinus node dysfunction.[2]
- Ischemic or nonischemic cardiomyopathy, acute myocardial infarction (especially inferior MI, which supplies the AV node in most patients), and congenital heart disease.[2]
- Infection/inflammation of the conduction system — Lyme carditis, infective endocarditis with a perivalvular abscess, myocarditis, Chagas disease, acute rheumatic fever, diphtheria.[2]
- Infiltrative disease — cardiac amyloidosis, sarcoidosis, hemochromatosis, lymphoma.[2]
- Rheumatologic disease — systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis.[2]
- Surgical or procedural trauma — valve surgery, transcatheter aortic valve replacement (TAVR), septal myomectomy, catheter ablation.[2]
- Metabolic/endocrine — hyperkalemia, hypokalemia, acidosis, hypothyroidism, hyperthyroidism, adrenal disease; also hypothermia and hypoxemia/hypercarbia (including obstructive sleep apnea).[2]
- Autonomic causes — carotid sinus hypersensitivity, neurally-mediated (vasovagal) syncope, situational syncope (cough, defecation, micturition, vomiting), sleep, and high-level athletic conditioning.[2]
- Congenital complete AV block associated with maternal systemic lupus erythematosus (anti-Ro/SSA antibodies) — see Special Populations.[2]
The pharmacist-critical differential — drug-induced and drug-exacerbated bradycardia
Medications are one of the most common, and most correctable, contributors to bradycardia — but as the treatment-decision sections below make clear, "the drug list includes this patient's medication" is a starting point for investigation, not a diagnosis on its own.
| Drug class | Examples | Mechanism | Pharmacist-relevant notes |
|---|---|---|---|
| Beta-blockers (including ophthalmic) | metoprolol, bisoprolol, other systemic beta-blockers, and timolol eye drops for glaucoma | Blocks beta-1-mediated sinus node automaticity and AV conduction | Ophthalmic beta-blockers are absorbed systemically enough to cause clinically significant bradycardia — a combination easy to miss when a medication review only scans oral drugs.[2] |
| Non-dihydropyridine calcium channel blockers | diltiazem and verapamil | Blocks L-type calcium channels in the sinus and AV nodes, slowing conduction | Additive with beta-blockers on the AV node; the combination has produced severe bradycardia, high-grade AV block, hypotension, and heart failure and should be used with real caution, if at all, together.[2] |
| Digoxin | digoxin | Increases vagal tone at the SA and AV nodes at therapeutic levels; markedly worse at toxic levels | Toxicity risk rises with hypokalemia, hypomagnesemia, and renal impairment, and with interacting drugs (amiodarone, verapamil, and dronedarone all raise digoxin levels). |
| Amiodarone and other antiarrhythmics | amiodarone, dronedarone, sotalol, flecainide, propafenone, quinidine, procainamide, adenosine | Direct depression of sinus node automaticity and/or AV conduction, mechanism varies by agent | Amiodarone is the most commonly encountered offender given its long half-life and widespread use; its effect can persist for weeks after the last dose.[2] |
| Ivabradine | ivabradine | Selective inhibition of the sinus node If (funny) current — heart-rate reduction is the drug's entire therapeutic mechanism, not a side effect | Contraindicated at a resting heart rate under 70 bpm before starting, in sick sinus syndrome, SA block, or third-degree AV block, and specifically contraindicated in combination with verapamil or diltiazem.[4] |
| Cholinesterase inhibitors | donepezil, rivastigmine, galantamine | Increased vagal tone at the AV node from peripheral acetylcholinesterase inhibition | A real, dose-related bradycardia/fall/syncope risk exists at the individual-patient level (highest with high-dose donepezil), even though a large Ontario population study found no net increase — in fact a reduction — in pacemaker insertion overall; see Special Populations for both findings in full.[5][6] |
| Other / additive risk | Clonidine, methyldopa, lithium, opioids, phenothiazine antiemetics/antipsychotics, tricyclic antidepressants, SSRIs, phenytoin, cannabis, propofol, succinylcholine | Varies by agent — central sympatholytic, direct nodal, or vagotonic effects | Most often relevant in combination with one of the drugs above rather than alone — review the full regimen, not just the most obvious culprit.[2][7] |
Red Flags & Refer
Escalate or refer urgently for any of the following:
- Hemodynamic instability from bradycardia — hypotension, altered mentation, ischemic chest pain, acute pulmonary edema, or shock — is a medical emergency; treat per the acute algorithm below and do not wait for an outpatient work-up.
- Syncope, particularly without a clear vasovagal trigger, in a patient with documented or suspected bradycardia or conduction disease — see the Syncope chapter for the broader syncope work-up; here, treat any syncope with a confirmed or strongly suspected bradyarrhythmic cause as a reason to expedite cardiology referral rather than observe.
- Newly identified Mobitz type II second-degree AV block, advanced/high-grade AV block, or third-degree (complete) AV block not clearly explained by a reversible or physiologic cause — refer urgently for pacing evaluation regardless of symptoms; do not manage expectantly in the community.[2][1]
- Second- or third-degree AV block complicating an acute (especially inferior) myocardial infarction — manage as an ACS emergency; see the Acute Coronary Syndromes chapter.
- Suspected digoxin toxicity with severe bradycardia, high-degree AV block, a life-threatening arrhythmia, or significant hyperkalemia — this needs digoxin immune Fab and emergency assessment, not simply holding the next dose and monitoring at home.
- New left bundle branch block, or any bradycardia/conduction abnormality with suspected underlying structural, infiltrative, or ischemic heart disease — needs echocardiography and cardiology referral.[2]
- Bradycardia identified after a recent cardiac procedure (valve surgery, TAVR, catheter ablation) — a meaningful share of post-procedural AV block resolves on its own, but this needs monitored in-hospital assessment, not outpatient management.[2]
Assessment & Diagnosis
History, examination, and medication reconciliation
Characterize the symptoms and their temporal relationship to activity, rest, and sleep; ask specifically about syncope and exertional tolerance. A complete medication reconciliation is a core diagnostic step here, not an afterthought — include every prescription and OTC product, and specifically ask about ophthalmic beta-blocker drops (e.g., timolol) for glaucoma, which are easy to miss on a list that only scans oral medications but are absorbed systemically enough to cause clinically significant bradycardia.[2] Ask about recent dose changes, newly started interacting drugs, and any recent decline in renal function.
Working definitions
| Term | Definition |
|---|---|
| Sinus bradycardia | Sinus rate under 50 bpm (the pathology-oriented definition used for sinus node dysfunction, distinct from the general <60 bpm clinical bradycardia threshold) |
| Sinus pause / sinus arrest | No sinus depolarization for more than 3 seconds (pause); no evidence of sinus depolarization at all (arrest) |
| Tachycardia-bradycardia syndrome | Sinus bradycardia, ectopic atrial bradycardia, or sinus pause alternating with an atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) |
| Chronotropic incompetence | Inability of the heart rate to rise appropriately with activity or demand — commonly defined as failing to reach 80% of the expected heart-rate reserve on exercise testing |
| First-degree AV block | PR interval >200 ms with 1:1 conduction (no beats are actually blocked) |
| Second-degree AV block, Mobitz type I (Wenckebach) | Progressively lengthening PR interval culminating in a single nonconducted P wave |
| Second-degree AV block, Mobitz type II | A single nonconducted P wave with constant PR intervals before and after (excluding 2:1 block) |
| Advanced/high-grade AV block | 2 or more consecutive P waves fail to conduct despite evidence of some remaining AV conduction |
| Third-degree (complete) AV block | No evidence of AV conduction at all — P waves and QRS complexes are each regular but fully dissociated |
Extended monitoring and functional testing
- Ambulatory ECG monitoring (24-48 hour Holter, external event/patch monitor, or implantable loop recorder) when symptoms are intermittent and not captured on a resting ECG.
- Exercise stress testing to assess the chronotropic response, and — where the AV block site is ambiguous (e.g., 2:1 block) — to help distinguish AV-nodal from infranodal conduction.[2]
- Electrophysiology study, reserved for cases where the site of block remains unclear after noninvasive testing and the answer would genuinely change management.[2]
Laboratory testing
- TSH (hypothyroidism is a reversible cause) and electrolytes (potassium, magnesium, calcium).
- Renal function in every patient, and specifically a digoxin level (drawn at least 6-8 hours post-dose) and renal function in any patient on digoxin presenting with bradycardia or new AV block.
- Troponin and serial ECGs if myocardial ischemia is suspected as the precipitant.
- Screen for obstructive sleep apnea symptoms in nocturnal or otherwise unexplained bradycardia.[2]
Echocardiography
Recommended newly identified left bundle branch block, Mobitz type II second-degree AV block, advanced/high-grade AV block, or third-degree AV block, with or without apparent structural or coronary disease. Reasonable other bradycardia or conduction disorders if structural heart disease is otherwise suspected. Not indicated routinely asymptomatic sinus bradycardia or first-degree AV block with no other clinical evidence of structural heart disease.[2]
Treatment Targets
- Distinguish physiologic from pathologic bradycardia, and reversible/drug-induced from intrinsic conduction disease, before committing to permanent therapy.
- Establish a genuine temporal correlation between symptoms and bradycardia — neither guideline requires a minimum heart rate or pause duration to justify pacing in an asymptomatic patient.[1][2]
- Stabilize acute symptomatic bradycardia promptly with pharmacologic therapy and pacing as needed, without delaying pacing preparation while waiting to see whether a drug effect wears off.[2]
- Identify and correct genuinely reversible causes — including medications, hypothyroidism, electrolyte disturbance, ischemia, and sleep apnea.[1][2]
- Recognize when a drug is unlikely to be the sole explanation — particularly for Mobitz II, advanced, or third-degree AV block — and avoid delaying a genuinely indicated pacemaker while waiting for a drug washout trial that is unlikely to resolve the underlying problem.[3]
- Provide permanent pacing without unnecessary delay for Mobitz II, advanced/high-grade, or third-degree AV block not explained by a reversible or physiologic cause, regardless of symptoms.[2][1]
- Avoid unnecessary permanent pacing for physiologic or genuinely asymptomatic bradycardia.[2]
- Screen for and treat obstructive sleep apnea in patients with sleep-related or otherwise unexplained bradycardia.[2]
- Practice shared decision-making with the patient (and, where relevant, their substitute decision-maker) once a guideline-based indication for pacing exists.[2]
Choose Initial Treatment
Moderate-to-severe symptoms (hypotension, altered mentation, ischemic chest pain, shock, or acute heart failure) atropine 0.5-1 mg IV, repeated every 3-5 minutes to a maximum total dose of 3 mg, while simultaneously assessing for and treating reversible causes.[2] Do not give atropine after heart transplantation — the transplanted heart is denervated and will not respond to a vagolytic drug; go directly to a beta-agonist infusion, aminophylline, or pacing instead.[2]
If atropine is ineffective, or the cause is a specific drug toxicity, move directly to a targeted agent rather than repeating atropine past the maximum dose: Calcium channel blocker overdose IV calcium (chloride or gluconate) — see Drug Tables. Beta-blocker or calcium channel blocker overdose glucagon and/or high-dose insulin euglycemic therapy — see Drug Tables. Digoxin toxicity digoxin immune Fab — see Drug Tables. General second-line (non-toxicologic) a dopamine or epinephrine infusion, or isoproterenol.[2]
Refractory to pharmacologic therapy, or severe symptoms/hemodynamic instability from the outset transcutaneous pacing without delay, followed by transvenous pacing if needed; in known or suspected drug toxicity with severe symptoms, prepare for pacing simultaneously with pharmacologic treatment rather than waiting to see whether the antidote works first.[2] Second- or third-degree AV block complicating an acute inferior myocardial infarction, when pacing is not immediately available aminophylline 250 mg IV bolus is a reasonable temporizing option.[2]
Symptomatic sinus node dysfunction not caused by a reversible or physiologic cause permanent pacemaker implantation is recommended.[1] Asymptomatic sinus bradycardia or sinus pauses from physiologically elevated vagal tone (including athletic conditioning), or sleep-related bradycardia/transient nocturnal pauses without another pacing indication permanent pacing should not be performed.[2]
Mobitz type II second-degree AV block, advanced/high-grade AV block, or third-degree (complete) AV block, not explained by a reversible or physiologic cause permanent pacing is recommended regardless of symptoms.[2][1] First-degree AV block, Mobitz type I second-degree AV block, or other AV block not meeting the criteria above permanent pacing only if symptoms genuinely correlate with the block, in the absence of a condition associated with progressive conduction disease.[2]
The decision to pace rests on three elements working together, not any one alone: an absolute anatomic indication (e.g., complete heart block, advanced infranodal block), a genuine correlation between symptoms and the arrhythmia, and persistence of the abnormality despite addressing reversible causes.[1]
A drug appearing on the list in Risk Factors is a starting point for investigation, not an automatic explanation — the correct next step differs by what is actually found on the ECG.
Sinus bradycardia or sinus node dysfunction, no AV block, a plausible temporal relationship to a causative or interacting drug a genuinely reasonable first step is dose reduction, spacing or removing an interacting agent (most often a non-dihydropyridine calcium channel blocker layered onto an existing beta-blocker, or ivabradine combined with either), or deprescribing the lowest-value agent — followed by a follow-up ECG and symptom review to confirm the correction actually worked, rather than assuming it did.
Digoxin check a level and renal function, hold the dose, and reassess; do not simply restart at the same dose without addressing the precipitant (renal decline, a new interacting drug, hypokalemia).
Mobitz II, advanced/high-grade, or third-degree (complete) AV block found in a patient on one of these drugs do not assume the drug is the sole cause and manage by stopping it alone. True drug-induced advanced AV block is uncommon, and recurrence after discontinuing the presumed culprit is common — the abnormality more often unmasks pre-existing, and often progressive, conduction disease than it reflects a purely reversible drug effect. Refer for pacing evaluation without waiting for a drug washout trial to prove the point, especially in frail or older patients, for whom a delay to arrange temporary pacing while waiting on a drug effect to clear carries a real, avoidable risk.[3]
Non-Pharmacologic Treatment
- Permanent pacemaker implantation is the definitive treatment for bradycardia meeting the indications above — it is genuinely first-line therapy here, not a last resort.
- Choose a physiologic pacing mode (dual-chamber pacing, or His-bundle/conduction-system pacing) over single-chamber right ventricular pacing where an appreciable ventricular pacing burden is expected in a patient with reduced-to-mid-range ejection fraction, to avoid pacing-induced cardiomyopathy.[2]
- Temporary transcutaneous pacing, escalating to transvenous pacing, bridges acute symptomatic bradycardia until the cause resolves or a permanent device is placed.
- Screen for and treat obstructive sleep apnea (CPAP, weight loss) in patients with sleep-related or otherwise unexplained bradycardia — this is a Class I recommendation, not an afterthought, and treating the sleep apnea itself may resolve the bradycardia.[2]
- Reassurance without treatment is appropriate for asymptomatic physiologic bradycardia — most commonly athletic conditioning — once an appropriate heart-rate response to exertion is confirmed and no red-flag symptoms are present.
- Address the underlying structural, ischemic, infiltrative, or rheumatologic disease directly when one is identified (e.g., treat active Lyme carditis, manage sarcoidosis) rather than treating the bradycardia in isolation.
- Do not order echocardiography or other advanced cardiac imaging routinely in asymptomatic sinus bradycardia or first-degree AV block without other evidence of structural heart disease.[2]
Special Populations
Pregnancy
Congenital complete heart block associated with maternal anti-Ro/SSA antibodies (most often in the context of Sjögren syndrome or systemic lupus erythematosus) is a recognized, though uncommon, cause of fetal and neonatal bradycardia.[2] Avoid unnecessary changes to a stable maternal cardiac medication regimen in pregnancy; where a bradycardia-associated drug genuinely must be continued or started, monitor maternal heart rate and symptoms as in any other patient and coordinate care with obstetrics and cardiology.
Breastfeeding
Atropine, dopamine, epinephrine, and isoproterenol are acute-setting drugs and not a routine breastfeeding consideration. Digoxin at standard maintenance doses is generally considered compatible with breastfeeding; confirm specifics against its own Drug Database entry.
Older adults, frailty, and cholinesterase inhibitors
Advancing age is itself the leading risk factor for both sinus node dysfunction and AV block, through progressive fibrosis of the conduction system.[2] This is also where the cholinesterase-inhibitor question comes up most often, and the honest answer has two genuinely true parts that need to be held together rather than picked apart. At the individual-patient level, a US Veterans Affairs cohort of 11,328 patients with dementia found cholinesterase inhibitor use associated with a real increase in bradycardia risk (adjusted HR 1.4, 95% CI 1.1-1.6), with a clear dose-response relationship for donepezil specifically — the highest-dose group carried the greatest risk (HR 2.1, 95% CI 1.5-2.9) — and patients who developed bradycardia were more likely to fall, have syncope, or need a pacemaker.[5] At the population level, a much larger Ontario, Canada study of 2,353,909 community-dwelling seniors found the opposite direction of effect on the outcome that matters most practically: cholinesterase inhibitor use was associated with a significantly lower, not higher, rate of pacemaker insertion (unadjusted HR 0.58, 95% CI 0.55-0.61), a finding that held after adjustment.[6] Both are correct at once — most patients tolerate these drugs without ever needing a pacemaker, but individual bradycardia, falls, and syncope are real, dose-related risks worth actively monitoring for, especially at higher donepezil doses, rather than dismissing the concern because the population-level signal looks reassuring.
Renal impairment
Reduce the digoxin maintenance dose and monitor levels more closely as renal function declines — see the Drug Database for specific adjustment. Consult a renal dosing reference or pharmacist for other renally cleared agents used in this chapter.
Hepatic impairment
Ivabradine is contraindicated in severe hepatic impairment.[4]
Post-cardiac surgery and TAVR
Transient AV block is common immediately after valve surgery, TAVR, or catheter ablation, and temporary epicardial or transvenous pacing wires are typically placed proactively; a meaningful minority of patients go on to need a permanent pacemaker. Monitor per institutional protocol before assuming the block will resolve on its own.[2]
Monitoring & Follow-Up
- Confirm resolution with a follow-up ECG and symptom review after any dose reduction or deprescribing undertaken because a drug was suspected of causing bradycardia — do not assume success without checking.
- Counsel patients started or continued on a bradycardia-associated drug on symptom awareness (dizziness, near-syncope, unusual fatigue) and when to seek care.
- Provide fall-risk counselling and, where relevant, driving-restriction guidance after any syncopal or near-syncopal episode attributable to bradycardia — follow local/provincial driving-fitness requirements.
- For patients with a new permanent pacemaker: confirm device follow-up (in-clinic and/or remote monitoring) is arranged, and counsel on recognizing signs of a device or lead complication (unusual pocket pain, swelling, or recurrent symptoms).
- Reinforce adherence and confirm understanding of the dose-titration instructions for ivabradine specifically, given its heart-rate-triggered up/down titration schedule.[4]
- Screen for, and revisit adherence with, obstructive sleep apnea treatment at follow-up when relevant.[2]
- For patients on digoxin: confirm a follow-up level and renal function check after any dose change or the addition of an interacting drug.
Common Errors to Avoid
- Assuming that any bradycardia in a patient on a beta-blocker, non-dihydropyridine calcium channel blocker, digoxin, or antiarrhythmic is simply "the drug," and stopping it alone without further work-up — especially dangerous for Mobitz II, advanced, or third-degree AV block, where true drug causation is uncommon and recurrence after discontinuation is common.[3]
- Giving atropine to a heart transplant recipient — the denervated heart will not respond.[2]
- Missing an ophthalmic beta-blocker (e.g., timolol eye drops for glaucoma) on medication reconciliation because the review only scanned oral medications.[2]
- Treating asymptomatic athletic bradycardia as a disease requiring investigation or pacing.[2]
- Combining a non-dihydropyridine calcium channel blocker with a beta-blocker, or either with ivabradine, without a clear plan for monitoring heart rate — these combinations are additive on the AV node and, for ivabradine plus verapamil or diltiazem specifically, contraindicated outright.[4]
- Starting or continuing digoxin without checking renal function and a level when bradycardia or new AV block appears, or restarting at the same dose without addressing the precipitant.
- Delaying pacing evaluation in a frail or older patient with advanced AV block "to see if it's the medication," when the evidence shows recurrence is common and true drug causation is the exception rather than the rule for this specific block pattern.[3]
- Ordering echocardiography or other advanced imaging routinely for asymptomatic sinus bradycardia or first-degree AV block without other evidence of structural heart disease.[2]
- Dismissing a genuine, dose-related bradycardia signal from a cholinesterase inhibitor because a population-level study shows an overall lower pacemaker rate — the population finding does not rule out a real reaction in the specific patient in front of you.[5][6]
- Overlooking obstructive sleep apnea screening in a patient with nocturnal or otherwise unexplained bradycardia.[2]
Clinical Decision Algorithm
Drug Tables
Acute Management of Symptomatic Bradycardia
First-line and second-line agents for moderate-to-severe symptomatic bradycardia, per the 2018 ACC/AHA/HRS acute management table.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Atropine | 0.5-1 mg IV; repeat every 3-5 minutes to a maximum total dose of 3 mg | Dry mouth, blurred vision, urinary retention, confusion in older adults | Additive anticholinergic burden with other anticholinergic drugs | First-line. Do not use after heart transplantation — the denervated heart will not respond.[2] |
| Dopamine | 5-20 mcg/kg/min IV infusion, starting at 5 mcg/kg/min and increasing by 5 mcg/kg/min every 2 minutes | Tachyarrhythmias, vasoconstriction or ischemia at higher doses | Additive hypertension with other vasopressors/sympathomimetics | Second-line if atropine is ineffective or unavailable; doses above 20 mcg/kg/min risk vasoconstriction or arrhythmia.[2] |
| Isoproterenol | 20-60 mcg IV bolus, then 10-20 mcg doses, or an infusion of 1-20 mcg/min titrated to heart-rate response | Ischemic chest pain, tachyarrhythmias | Additive tachyarrhythmia risk with other sympathomimetics | A pure beta-agonist without atropine's anticholinergic effects; monitor for ischemic chest pain.[2] |
| Epinephrine | 2-10 mcg/min IV, or 0.1-0.5 mcg/kg/min IV, titrated to effect | Tachyarrhythmias, hypertension, increased myocardial oxygen demand | Additive hypertension/tachyarrhythmia with other vasopressors/sympathomimetics | An equally reasonable alternative to dopamine when atropine fails.[2] |
Antidotes for Drug-Induced Bradycardia and AV Block
Targeted therapy for a specific, identified toxicologic cause — used alongside, not instead of, atropine and pacing readiness.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Glucagon | 3-10 mg IV, then an infusion of 3-5 mg/hour | Nausea, vomiting, hyperglycemia | None significant at standard doses | Beta-blocker or calcium channel blocker overdose — bypasses the blocked beta-receptor through a separate signalling pathway.[2] |
| High-dose insulin (euglycemic therapy) | 1 unit/kg IV bolus, then an infusion of 0.5 units/kg/hour | Hypoglycemia, hypokalemia | None significant at standard doses | Beta-blocker or calcium channel blocker overdose, particularly if refractory; monitor glucose and potassium closely.[2] |
| Calcium chloride 10% | 1-2 g IV every 10-20 minutes, or an infusion of 0.2-0.4 mL/kg/hour | Tissue necrosis with extravasation, hypercalcemia | Precipitates with IV bicarbonate; do not co-administer through the same line | Calcium channel blocker overdose. Give through a central line where possible; roughly 3 times the elemental calcium per mL of the gluconate salt.[2] |
| Calcium gluconate 10% | 3-6 g IV every 10-20 minutes, or an infusion of 0.6-1.2 mL/kg/hour | Hypercalcemia; less tissue-necrosis risk with extravasation than the chloride salt | Precipitates with IV bicarbonate; do not co-administer through the same line | Calcium channel blocker overdose — preferred over calcium chloride for peripheral IV administration.[2] |
| Digoxin immune Fab | Individualized to the amount ingested or the known digoxin level; each vial binds approximately 0.5 mg of digoxin; infuse over at least 30 minutes; may repeat | Hypokalemia as toxicity resolves, potential rebound toxicity if underdosed, hypersensitivity | Falsely elevates subsequent digoxin level assays — do not use a post-treatment level to guide re-dosing without accounting for this | Digoxin toxicity with severe bradycardia, high-degree AV block, a life-threatening arrhythmia, or significant hyperkalemia. Do not delay for a confirmatory level in a severe presentation.[2] |
| Aminophylline | 250 mg IV bolus (2nd/3rd-degree AV block with acute inferior MI); 6 mg/kg IV over 20-30 minutes (post-heart-transplant or spinal-cord-injury-associated bradycardia) | Tachyarrhythmias, nausea, seizures at high levels | Numerous CYP1A2/CYP3A4-mediated interactions — review before use | A reasonable temporizing measure only, when pacing is not immediately available — does not substitute for pacing.[2] |
| Theophylline | 300 mg IV, then an oral dose of 5-10 mg/kg/day titrated to effect; therapeutic level 10-20 mcg/mL | Nausea, vomiting, headache, tremor, tachyarrhythmias at excess levels | Numerous CYP1A2/CYP3A4-mediated interactions (levels reduced by phenytoin, carbamazepine, rifampin, and smoking; increased by macrolides and quinolones) | Post-heart-transplant maintenance option after an initial aminophylline bolus; requires serum level monitoring.[2] |
References
- The Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Selection, Implantation, and Management of Patients With Cardiac Implantable Electronic Devices — Canadian Journal of Cardiology, Canadian Cardiovascular Society/Canadian Heart Rhythm Society (Andrade JG, Joza J, et al.). Can J Cardiol 2026;42(1):1-68
- 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay — Journal of the American College of Cardiology, American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society (Kusumoto FM, Schoenfeld MH, et al.). J Am Coll Cardiol, Nov 2018
- Clinical Significance and Management of Atrioventricular Block Associated With Bradycardic/Antiarrhythmic Drug Therapy: Drug-Induced or Drug-Revealed? — Journal of Cardiovascular Electrophysiology (Sfairopoulos D, Bazoukis G, Sideris S, Fragakis N, Letsas K, Zekios K, Liu T, Korantzopoulos P). J Cardiovasc Electrophysiol 2025;36(7):1643-1653
- LANCORA (ivabradine tablets) Product Monograph — Servier Canada Inc. / Health Canada Drug Product Database. Health Canada Product Monograph, Date of Authorization 2025-05-30
- Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the Veterans Affairs New England Healthcare System — Journal of the American Geriatrics Society (Hernandez RK, Farwell W, Cantor MD, Lawler EV). J Am Geriatr Soc 2009;57(11):1997-2003
- The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada — BMC Neurology (Huang AR, Redpath CJ, van Walraven C). BMC Neurol 2015;15:66
- Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association — Circulation, American Heart Association (Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, et al.). Circulation 2020;142(15):e214-e233
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.